Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation.
Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TKS, de Clerck E, Polivka J, Potuznik P, Polivka J, Stetkarova I, Kubatka P, Thumann G. · 2023
Read Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation. by Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TKS, de Clerck E, Polivka J, Potuznik P, Polivka J, Stetkarova I, Kubatka P, Thumann G. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9971534.txt.
Introduction
Kropp and co-authors frame diabetic retinopathy as a leading cause of blindness and an early warning sign. Proliferative disease is the advanced sequel of this diabetes complication. It blinds many people of working age. Current screening often misses disease until damage cannot be reversed.
Small vessel disease and nerve changes in the retina feed each other. The cycle brings mitochondrial harm, chronic inflammation, and new vessel growth. Vision field shrinks as damage grows. The authors call this a domino effect across diabetes complications. Retinopathy can predict later events such as ischemic stroke. They argue for mitochondrial health checks in care. Multi-omic tear fluid analysis may aid early detection and risk control.
Catalog record
| CREATOR | Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TKS, de Clerck E, Polivka J, Potuznik P, Polivka J, Stetkarova I, Kubatka P, Thumann G. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 100 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications—risks and mitigation By Martina Kropp, Olga Golubnitschaja, Alena Mazurakova, Lenka Koklesova, Nafiseh Sargheini, Trong-Tin Kevin Steve Vo, Eline de Clerck, Jiri Polivka, Pavel Potuznik, Jiri Polivka, Ivana Stetkarova, Peter Kubatka Published in: The EPMA Journal DOI: 10.1007/s13167-023-00314-8 ABSTRACT Proliferative diabetic retinopathy (PDR) the sequel of diabetic retinopathy (DR), a frequent complication of diabetes mellitus (DM), is the leading cause of blindness in the working-age population. The current screening process for the DR risk is not sufficiently effective such that often the disease is undetected until irreversible damage occurs. Diabetes-associated small vessel disease and neuroretinal changes create a vicious cycle resulting in the conversion of DR into PDR with characteristic ocular attributes including excessive mitochondrial and retinal cell damage, chronic inflammation, neovascularisation, and reduced visual field. PDR is considered an independent predictor of other severe diabetic complications such as ischemic stroke. A “domino effect” is highly characteristic for the cascading DM complications in which DR is an early indicator of impaired molecular and visual signaling. Mitochondrial health control is clinically relevant in DR management, and multi-omic tear fluid analysis can be instrumental for DR prognosis and PDR prediction. Altered metabolic pathways and bioenergetics, microvascular deficits and small vessel disease, chronic inflammation, and excessive tissue remodelling are in focus of this article as evidence-based targets for a predictive approach to develop diagnosis and treatment algorithms tailored to the individual for a cost-effective early prevention by implementing the paradigm shift from reactive medicine to predictive, preventive, and personalized medicine (PPPM) in primary and secondary DR care management. PREAMBLE Diabetic retinopathy (DR) is, together with chronic kidney disease and peripheral neuropathy, the most frequent complication of diabetes mellitus (DM) [1] and the leading cause of blindness in the working-age population [2]. Current screening processes for the risk to develop DR are not sufficiently effective allowing the disease to progress undetected until irreversible damage has occurred [3–5]. DR is clinically defined as a microvascular disease that involves damage of the retinal capillaries with secondary visual impairment [6]. Due to a particular sensitivity of retinal cells to oxidative stress, profound retinal changes are an early event and reliable predictor of complications linked to DM, which can be monitored by electroretinography as functional consequences of microvasculopathy [7]. Further, small vessel disease and neuroretinal changes create a vicious cycle fostering the development of proliferative diabetic retinopathy (PDR) with characteristic attributes including excessive mitochondrial and retinal cell death, chronic inflammation, neovascularisation, and impaired visual field leading to blindness [8]. Moreover, it has to be noted that PDR is considered an independent predictor of other severe diabetic complications such as ischemic stroke [9–11]. Contextually, a “domino effect” is characteristic for the cascading DM complications with a key role of DR as the early indicator of impaired molecular and visual signaling (Fig. 1) [9].Fig. 1Diabetic retinopathy as an early event and a reliable predictor of severe complications linked to DM: the “domino” effect is characteristic for cascading diabetes-associated complications DR pathomechanisms are complex involving epi-/genetics and post-translational modifications, metabolic and signalling alterations, and subcellular and cellular alterations synergistically leading to retinal neurovascular dysfunction [8]. The hyperglycemia-induced systemic oxidative stress and redox imbalance are considered a causal risk of compromised mitochondrial health, and neural retina bioenergetics with vascular regression are reflected in DR pathogenesis [12]. Reactive oxygen species (ROS) overproduction, hyperactivation of inflammatory pathways, and increased mitochondrial and cellular death are characteristic for the DM-related retinal impairments [8]. The focus of this article is altered metabolomics and bioenergetics, microvascular and small vessel disease, chronic inflammation, and excessive tissue remodelling as evidence-based targets for a novel predictive approach with treatment algorithms tailored to the person and cost-effective early prevention to implement a paradigm shift from reactive medicine to preventive, predictive, and personalised medicine (PPPM) in primary and secondary DR care management. It will discuss the following:(A)DR: global statistics and trends(B)Association of DR with other diabetes-related complications(C)Major systemic risks and targets of DR(D)Targeted mitigation DR: GLOBAL STATISTICS AND TRENDS DM Noncommunicable diseases (NCDs) pose serious health challenges with a steadily growing burden for patients and health care systems. The most prevalent form of chronic NCD is DM type 2 (T2D) [13]. T2D is considered a serious public health concern that is reaching alarming rates throughout the world [14]. Rapid economic growth and urbanization have resulted in a growing burden of DM in all countries, regardless of their level of economic development and epidemiological or demographic diversity [15]. In addition to exerting a negative impact on an individual’s functional capacity and quality of life, diabetes results in significant morbidity and premature mortality. Over the past few years, it has been noted that more than one-third of diabetes-related deaths have occurred in people under the age of 60 [16]. It is estimated that 12% of global health expenditures, or $727 billion, are devoted to diabetes and its complications, and similar to the number of patients suffering from diabetes, there is an unsustainable increase in this costs [17]. Diabetes is a disease that is strongly associated with both microvascular (including retinopathy, nephropathy, and neuropathy) and macrovascular complications (such as ischemic heart disease, peripheral vascular disease, and cerebrovascular disease) resulting in organ and tissue impairment in about one-third to one-half of diabetic patients. Several biochemical changes may interact of which one key change is increased protein glycation. This process has a broad range of impacts on surrounding tissues, including modification (e.g., thickening) of collagen and endothelium [18]. In DR, protein glycation can promote apoptosis of retinal pericytes, overproduction of endothelial growth factors, increased neovascularisation, and vascular inflammation, contributing to an elevated risk of microthrombosis formation, capillary blockage, and retinal ischemia [19]. Furthermore, abnormal stimulation of signaling cascades (such as the protein kinase C pathway), excessive production of ROS, and abnormal activation of hemodynamic regulation systems (such as the renin-angiotensin system) play major roles in microvascular complications [20]. The global trends of DM and T2D Globally, DM prevalence has increased fivefold in the last four decades, from 108 million adults in 1980 to 537 million in 2021. Despite the World Health Organization’s (WHO) ambitions of reducing DM prevalence as well as premature mortality from NCDs by one-third by 2030, the outlook does not seem to be positive [21]. The number of people living with DM worldwide will increase to 643 million by 2030 and 783 million by 2045, even if age-specific prevalence remains constant [22]. In 2017, approximately 1 in 11 European adults had T2D [16], a figure projected to grow to almost 66 million by 2030 and 68 million by 2045 [23], considering that T2D accounts for 90–95% of all diabetes cases [13]. Worldwide, more than 462 million people were affected by T2D in 2017, representing 6.28% of the world’s population (4.4% of 15–49 year olds, 15% of 50–69 year olds, and 22% of 70 plus year olds) [16]. Over the past two decades, T2D-related mortality has risen dramatically; in 1990, it was the eighteenth leading cause of death, while in 2017, it ranked the ninth [21]. Moreover, it is estimated that 541 million adults suffer from impaired glucose tolerance, which puts them at high risk for developing T2D [17]. Previously confined to affluent